| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/18/2001 | US6290952 Method of dephosphorylating an endotoxin in vivo with alkaline phosphatase |
| 09/18/2001 | US6290948 Using certain chemokines or biologically active fragments thereof alone or in conjunction with an anti-infective agent or hematopoietic maturing agent. |
| 09/18/2001 | US6290947 In one embodiment, the polymer is a copolymer comprising a monomer having a pendant ammonium group and a hydrophobic monomer. |
| 09/18/2001 | US6290946 Administering to the animal a therapeutically effective amount of a polymer having a plurality of pendant acid functional groups which are directly attached to the polymer backbone or attached to the polymer backbone by a spacer group. |
| 09/18/2001 | US6290934 Agent for the promotion of oral hygiene and oral health |
| 09/18/2001 | US6290931 The spray drying process, since the evaporation of the solvent takes place within fractions of a second, is an extremely gentle process precisely for thermally vulnerable steroids (such as sulfamate steroids). |
| 09/18/2001 | US6290930 Cosolvent, especially ethanol, present in an amount that dissolves or solubilizes the budesonide in the mixture of cosolvent and propellant. |
| 09/18/2001 | US6290929 Cancer treatment |
| 09/18/2001 | US6290712 Laser/sensitizer assisted immunotherapy |
| 09/18/2001 | US6289892 Partial liquid breathing of fluorocarbons |
| 09/18/2001 | US6289745 High temperature insertion type flow element and mounting extension |
| 09/18/2001 | CA2238879C Thereapeutic applications for the anti-t-bam (cd40-l) monoclonal antibody 5c8 |
| 09/18/2001 | CA2236814C Quinoline and quinazoline compounds useful in therapy |
| 09/18/2001 | CA2231118C Pharmaceutical preparation containing nimesulide for topical use |
| 09/18/2001 | CA2168364C Stabilized pharmaceutical composition containing bupropion |
| 09/18/2001 | CA2046050C Bis[4-(2,6-di-alkyl)phenol]silane derivatives as antiatherosclerotic agents |
| 09/18/2001 | CA2045783C 9-purinyl phosphonic acid derivatives |
| 09/18/2001 | CA2039056C 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents |
| 09/18/2001 | CA2031385C Extract from ginkgo biloba leaves, its method of preparation and pharmaceuticals containing the extract |
| 09/18/2001 | CA2026890C Quinoline derivatives, their production and use |
| 09/18/2001 | CA2022297C Derivatives of 1,2,3,4-tetrahydro-9-acridinamine |
| 09/15/2001 | WO2001068859A2 Il-17 receptor like molecules and uses thereof |
| 09/15/2001 | WO2001066747A2 Proteins named fctrx and nucleic acids encoding same |
| 09/15/2001 | CA2403370A1 Il-17 receptor like molecules and uses thereof |
| 09/15/2001 | CA2401552A1 Proteins named fctrx and nucleic acids encoding same |
| 09/15/2001 | CA2302446A1 Lormer's healing balm |
| 09/14/2001 | CA2339677A1 Product for the treatment of erectile dysfunction and its use |
| 09/13/2001 | WO2001067107A1 Modulation of histone deacetylase |
| 09/13/2001 | WO2001066772A2 Heparinase iii and uses thereof |
| 09/13/2001 | WO2001066741A2 Kcnb: a novel potassium channel protein |
| 09/13/2001 | WO2001066721A2 Nucleic acid sensor molecules |
| 09/13/2001 | WO2001066716A1 Polypeptide having phosphodiesterase activity |
| 09/13/2001 | WO2001066706A1 Protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | WO2001066697A2 Serum free cultivation of primate embryonic stem cells |
| 09/13/2001 | WO2001066607A1 Crosslinked anion-exchange resin or salt thereof and phosphorus adsorbent comprising the same |
| 09/13/2001 | WO2001066606A1 Crosslinked anion-exchange resin or salt thereof |
| 09/13/2001 | WO2001066597A2 Inflammation-related gene |
| 09/13/2001 | WO2001066595A2 Human fgf-23 gene and gene expression products |
| 09/13/2001 | WO2001066572A2 Polynucleotides isolated from e. coli of nature b2/d+ a-, and uses thereof |
| 09/13/2001 | WO2001066561A1 Preventive or therapeutic drugs for eye diseases |
| 09/13/2001 | WO2001066560A2 Novel derivatives comprising phytosterols and/or phytostanols and alpha-lipoic and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders |
| 09/13/2001 | WO2001066557A1 Adam polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | WO2001066553A2 Novel aryl fructose-1,6-bisphosphatase inhibitors |
| 09/13/2001 | WO2001066551A2 Azole compounds as therapeutic agents for fungal infections |
| 09/13/2001 | WO2001066550A2 Compounds for pdt |
| 09/13/2001 | WO2001066548A1 New aza-indolyl derivatives |
| 09/13/2001 | WO2001066545A2 1,8-NAPHTHALIMIDE IMIDAZO[4,5,1-de]ACRIDONES WITH ANTI-TUMOR ACTIVITY |
| 09/13/2001 | WO2001066544A2 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers |
| 09/13/2001 | WO2001066543A2 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives |
| 09/13/2001 | WO2001066542A1 Pyridonecarboxylic acid derivatives |
| 09/13/2001 | WO2001066540A1 Imidazol-2-carboxamide derivatives as raf kinase inhibitors |
| 09/13/2001 | WO2001066539A1 Imidazol derivatives as raf kinase inhibitors |
| 09/13/2001 | WO2001066533A1 1,5-benzothiazepines and their use as hypolipidaemics |
| 09/13/2001 | WO2001066531A1 Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase |
| 09/13/2001 | WO2001066525A1 New ccr5 modulators: benzimidazoles or benzotriazoles |
| 09/13/2001 | WO2001066521A1 Azacyclic compounds for use in the treatment of serotonin related diseases |
| 09/13/2001 | WO2001066520A1 Indole derivatives, process for preparation of the same and use thereof |
| 09/13/2001 | WO2001066519A2 Method for preparing pyrimidone derivatives with antifungal activity |
| 09/13/2001 | WO2001066438A2 Pharmaceutical packaging system |
| 09/13/2001 | WO2001066214A1 Methods for extraction and reaction using supercritical fluids |
| 09/13/2001 | WO2001066148A1 A method of sensitising endothelial cells to prodrugs |
| 09/13/2001 | WO2001066146A1 Methods and compositions for dietary supplements |
| 09/13/2001 | WO2001066145A1 Anti-infective active substance combinations and the use thereof for the topical treatment of fungus diseases of toe and finger nails |
| 09/13/2001 | WO2001066144A2 Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity |
| 09/13/2001 | WO2001066143A1 Vasoactive agents |
| 09/13/2001 | WO2001066142A1 Preparations for chondrogenesis |
| 09/13/2001 | WO2001066140A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| 09/13/2001 | WO2001066129A1 Substances for the treatment of spinal muscular atrophy |
| 09/13/2001 | WO2001066123A2 Composition consisting of phy906 and chemotherapeutic agents |
| 09/13/2001 | WO2001066121A1 Oleoresin of hypericum perforatum l., method for obtaining said oleoresin and the use thereof |
| 09/13/2001 | WO2001066119A2 Pharmaceutical compositions including alginates |
| 09/13/2001 | WO2001066117A1 Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor |
| 09/13/2001 | WO2001066116A1 Method for modulating tumor growth and metastasis of tumor cells |
| 09/13/2001 | WO2001066115A2 Acetylsalicylic acid solutions |
| 09/13/2001 | WO2001066114A1 Novel methods using cholinesterase inhibitors |
| 09/13/2001 | WO2001066113A1 Metabotropic glutamate receptor antagonists for treating tolerance and dependency |
| 09/13/2001 | WO2001066112A1 Urease inhibitors |
| 09/13/2001 | WO2001066111A1 Compositions containing potential spla2 inhibitors for the treatment of pain |
| 09/13/2001 | WO2001066110A2 METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS |
| 09/13/2001 | WO2001066109A1 Oral pharmaceutical compositions containing n-sulphonylindoline derivatives |
| 09/13/2001 | WO2001066107A2 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 09/13/2001 | WO2001066106A1 A pharmaceutical composition having chlorogenic acid as active component for preventing or treating the declining of male reproduction capability |
| 09/13/2001 | WO2001066105A1 Method and composition for lightening the skin |
| 09/13/2001 | WO2001066104A2 Retinoid formulations for aerosolization and inhalation |
| 09/13/2001 | WO2001066103A2 Treatment of neoplasms by inhalation of carboplatin |
| 09/13/2001 | WO2001066102A2 Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same |
| 09/13/2001 | WO2001066101A2 Treatment of psoriasis |
| 09/13/2001 | WO2001066100A2 Pharmaceutical composition |
| 09/13/2001 | WO2001066099A2 Use of quinazoline derivatives as angiogenesis inhibitors |
| 09/13/2001 | WO2001066098A2 Therapeutic uses of ppar mediators |
| 09/13/2001 | WO2001066097A2 Active substance directed against microbes of the genus pseudomonas |
| 09/13/2001 | WO2001066096A2 Compositions for prevention and treatment of dementia |
| 09/13/2001 | WO2001066093A2 Sustained release ranolazine formulations |
| 09/13/2001 | WO2001066091A1 Method of preparing solid dispersions |
| 09/13/2001 | WO2001066089A2 Pharmaceutical compositions comprising cannabis |
| 09/13/2001 | WO2001066088A1 New self emulsifying drug delivery system |
| 09/13/2001 | WO2001066087A1 New self emulsifying drug delivery system |
| 09/13/2001 | WO2001066085A2 Micellar pharmaceutical compositions for buccal and pulmonary application |
| 09/13/2001 | WO2001066084A2 Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa |
| 09/13/2001 | WO2001066081A2 Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients |